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1. Abstract 
English 
Anti-PEG antibodies in experimental animal disease models and in 
patients treated with PEGylated proteins 
 
A number of protein therapeutics have been conjugated with polyethylene 
glycol (PEG) in order to increase the serum half-life and to reduce 
immunogenicity of these proteins. Examples are PEG-asparaginase, PEG-
interferons, PEG-filgrastim and PEG-adenosine deaminase. PEG is a 
hydrophilic, uncharged, inert, biocompatible synthetic polymer that has 
long been thought to be non-immunogenic. However, it was shown in 
recent reports that treatment with PEGylated protein therapeutics can lead 
to the development of anti-PEG antibodies in animal disease models and 
in patients. Those antibodies caused a rapid clearance of the PEGylated 
proteins from the circulation. Moreover, a considerable amount of anti-
PEG antibodies in healthy donors was reported in some studies.  
 
Based on these reports, we developed an analytical method based on a 
flow-cytometric approach to detect anti-PEG antibodies. Anti-PEG 
antibodies are detected by FACS analysis using polystyrene beads that 
are grafted with PEG and further conjugated with branched PEG reagent. 
We established the assay and used it for monitoring the development of 
anti-PEG antibodies in disease models in mouse and rat during preclinical 
studies of the new drug candidates that are developed by Baxter 
Innovations GmbH. Furthermore we showed, that our modification of the 
polystyrene beads with the additional PEGylation improved the assay in 
comparison to similar approaches.  
 
Moreover we used this assay to screen healthy blood donors for the 
potential presence of “natural” anti-PEG antibodies. This study in healthy 
blood donors provide important information for the screening of patients to 
be included in clinical studies of the new drug candidates. 
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Zusammenfassung 
Anti-Peg Antikörper in Tierversuchsmodellen und in Patienten die mit 
PEGylierten Proteinen behandelt werden 
 
Polyethylenglykol (PEG) ist ein hydrophiles, ungeladenes, inertes, 
biokompatibles synthetisches Polymer, welches heutzutage in vielen 
Gebieten zum Einsatz kommt. Eines dieser Anwendungsgebiete ist die 
Konjugierung von PEG an Protein- Therapeutika, um deren Halbwertszeit 
im Serum zu erhöhen. Beispiele für solche Therapeutika sind PEG - 
Asparaginase, PEG - Interferone, PEG - Filgrastim und PEG - Deaminase. 
PEG wird seit Jahrzehnten eingesetzt und galt lange Zeit als nicht 
immunogen. Neue Studien in Tierversuchsmodellen zeigten jedoch, daß 
es durch Behandlung mit PEGylierten Proteinen zur Entwicklung von anti-
PEG Antikörpern kommen kann, welche zu einer raschen Entfernung des 
PEGylierten Proteins aus der Blutzirkulation führten. Überdies wurde in 
einer Studie berichtet, daß ein weitaus größerer Anteil von gesunden 
menschlichen Plasmaspendern „natürliche“ anti-PEG Antikörper besitzt, 
als ursprünglich angenommen.  
 
Ziel dieser Arbeit war es, eine auf Durchflusszytometrie basierende, 
analytische Methode zum Nachweis von anti-PEG Antikörpern, zu 
etablieren. Dieser Nachweistest wurde dann in verschiedenen 
präklinischen Studien für derzeitige Produktkandidaten der Baxter 
Innovations GmbH verwendet, um die potentielle Entwicklung von anti-
PEG Antikörpern in verschiedenen Tierversuchsmodellen zu verfolgen. 
Anti-PEG Antikörper wurden mittels FACS Analyse über Polystyrol –
Kügelchen nachgewiesen, an deren Oberfläche lineares sowie 
verzweigtes (branched) PEG konjugiert wurde. 
 
Wir konnten zeigen, daß die Behandlung mit PEGylierten Proteinen im 
Tierversuchsmodellen zur Entwicklung von anti-PEG Antikörpern führen 
kann. Zusätzlich können wir bestätigen, daß der Prozentsatz an 
„natürlichen“ anti-PEG Antikörpern in gesunden humanen Plasmaproben 
weitaus höher ist, als ältere Studien vermuten ließen. Die vielleicht bereits 
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vorhandenen anti-PEG Antikörpern, sowie die potentielle Entwicklung von 
anti-PEG Antikörpern in Patienten nach Behandlung mit PEGylierten 
Proteinen, muß in Zukunft bei klinischen Studien mit PEGylierten 
Proteinen berücksichtigt werden. Außerdem konnten wir zeigen, daß 
unsere Modifikation der Polysterol – Kügelchen mit verzweigtem 
(branched) PEG eine Verbesserung der Empfindlichkeit des Tests im 
Vergleich zu ähnlichen Testverfahren darstellt. 
  Introduction 
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2. Introduction 
 
2.1 Coagulation System  
 
Coagulation is an important part of the hemostasis process by which blood 
forms solid clots after a blood vessel gets injured. Damage to small blood 
vessels and capillaries frequently occurs. There are three basic 
mechanisms that promote hemostasis and the termination of the bleeding. 
 
The first reaction after an injury is local vasoconstriction and compression 
of injured vessels, thus diminishing blood loss. There are several 
mechanism including endothelial cell nitric oxide and prostacyclin that 
promote blood fluidity by preventing platelet stasis and dilating intact blood 
vessels. Those factors are no longer existing at the site of vessel damage, 
thus leading to the second mechanism: the adherence of platelets. 
Platelets are cells that are derived from megakaryocytes. Blood normally 
contains 150,000 to 350,000 per micro liter (µl). If this value should drop 
much below 50,000/µl, there is a danger of uncontrolled bleeding. This is 
because of the essential role that platelets have in blood clotting. 
 
The starting point is the attachment of the soluble protein von Willebrand 
factor to the subendothelial matrix. There it exposes multiple intrinsic 
binding sites for the platelet specific membrane Glycoprotein Ib (GPIb). 
This binding stimulates platelet activation. The platelets expose the 
Glycoprotein IIbIIIa binding site for further attachment of von Willebrand 
factor and fibrinogen. Furthermore platelets undergo degranulation and 
release Adenosindiphosphate (ADP), which attracts more platelets to the 
area, serotonin and thromboxane A2, which cause vasoconstriction and 
Calcium. Thus ADP and thromboxane A2 promote more platelet adhesion 
and therefore more ADP and thromboxane. The positive feedback 
promotes the formation of a platelet plug. Calcium is essential in the 
activation of the soluble proteins of the coagulation pathway, which is the 
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final hemostatic mechanism. The plug formed by the platelets is relatively 
unstable and needs to be supported by a stronger clot, which is the final 
goal of the coagulation pathway. It leads to the generation of thrombin 
(factor IIa), which can then convert soluble fibrinogen into fibrin, which 
forms a clot (Colman et al, Hemostasis and Thrombosis 2001). 
 
Two coagulation pathways provide normal human hemostasis: the 
extrinsic and the intrinsic pathway, that converge on a single common final 
pathway resulting in a clot. They are playing an important role for 
regulation of coagulation and do differ in their trigger for activation. 
 
2.1.1 The intrinsic pathway 
All components of this pathway are found within the blood. The reactions 
take place on the membrane surface and are initiated by activation of the 
contact factors by a negatively charged surface – e.g. tissue material such 
as collagen on the exposed surface of a blood vessel. The first step of the 
cascade is the binding of coagulation factor XII (FXII), or Hageman factor, 
to a sub-endothelial surface exposed after injury. FXII is a serine protease 
produced by the liver that circulates in plasma as an inactive zymogen. At 
the same time a complex of prekallikrein and high molecular weight 
kininogen (HMWK) binds in close proximity to FXII to the surface leading 
to the activation of FXII by proteolytic cleavage of the native Hagemann 
factor into two chains (50 and 26 kDa). Both chains are still linked by a 
disulphide bond after cleavage. The light chain (26kDa) contains the active 
site and this molecule is known as activated factor XII (FXIIa) (Colman et 
al, Hemostasis and Thrombosis 2001). 
 
Once activated, FXIIa stays in contact with the surface and activates factor 
XI (FXI) by proteolytic cleavage. This step requires Ca++ to proceed 
efficiently and again HMWK, which binds to factor XI and facilitates the 
activation process. Furthermore FXIIa cleaves prekallikrein to end up with 
a higher amount of kallikrein, which also cleaves FXII: a positive feedback 
control loop has been established. 
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Activated factor XI (FXIa) assembles on the surface in complex with factor 
VIII (FVIII). This complex needs calcium to stabilize certain structures on 
these proteins associated with their membrane-binding properties. Factor 
X (FX) is binding the complex and is activated to FXa. After the activation 
of factor X we are talking about the Common Pathway, because all 
following steps are equal for the extrinsic pathway. 
 
Factor V (FV) interacts with factor Xa in the presence of calcium ions on a 
phospholipids membrane surface to accelerate the conversion of 
prothrombin (factor II) to thrombin by factor Xa. Thrombin is the enzyme 
that cleaves the soluble fibrinogen to monomer fibrin. Many fibrin 
molecules polymerize forming long fibres. Factor XIII promote bonding 
between the units of the polymer. 
 
2.1.2 The extrinsic pathway 
The extrinsic pathway is an alternative way to produce fibrin. It provides a 
very rapid response to tissue injury, generating activated factor X almost 
instantaneously, compared with the seconds, or even minutes, required for 
the intrinsic pathway to activate factor X. The main function of the extrinsic 
pathway is to augment the activity of the intrinsic pathway. 
 
Activation of this pathway occurs through protein tissue factor (tissue 
thromoblastin or factor III) that is normally not localized within the blood 
stream. Tissue factor is found on the surface of almost all cells, particularly 
abundant in the cells of brain, lungs and placenta (Drake et al 1989). Once 
activated, tissue factor binds rapidly to factor VII, which is then activated to 
form a complex of tissue factor, activated factor VII, calcium and platelet 
phospholipids. This complex then rapidly activates factor X. After 
activation of FX the common pathway is proceeding, leading to the 
generation of fibrin and a more stable clot. 
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2.1.3 Biochemistry of blood coagulation 
All proteins responsible for blood clotting after injury circulate in the blood 
as zymogens, which means they are in their inactive form. These 
precursor enzymes are cut at a specific bond that connects two amino 
acids within the polypeptide. The protein is split into specific fragments and 
an active enzyme is formed. This enzyme can split itself particular peptide 
bonds. This process is called limited proteolysis. 
 
Figure 1: Coagulation pathway overview 
Source: Dorland's Medical Dictionary for Health Consumers. © 2007 by Saunders, an imprint of 
Elsevier, Inc. 
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2.1.4 Regulation of blood coagulation 
Blood clotting is life essential but the active enzymes must be turned off 
and the clotting process contained locally to the area of tissue injury. For 
this purpose we have a complex system of a series of blood proteins that 
assure the disengaging of the activated blood-clotting system. 
 
For instance Antithrombin III is a plasma protein that binds most of the 
activated blood-clotting proteins in order to form inert complexes where the 
active site of the protease enzymes are inaccessible to its usual substrate. 
This action is greatly enhanced by the presence of heparin by inducing an 
allosteric change to antithrombin III. Heparin is a substance formed by 
mast cells of the connective tissue (Bjork I et al 1997) 
 
Protein C, a vitamin K-dependent protein, is a zymogen that requires 
vitamin K for its activation by thrombin complexed to thrombomodulin, a 
protein on the endothelial cell membrane. Activated protein C is capable of 
inactivating the active cofactor forms of factors VIII and V. Its action is 
enhanced when bound protein S, a vitamin K-dependent protein that is 
attached to cell membranes (platelet or possibly endothelial cells). A 
deficiency in the level of protein C or protein S is associated with an 
excessive tendency to form clots (Griffin et al 2007) 
 
Another anticoagulant effect is the fibrinolytic (fibrin-splitting) action of 
plasmin, an enzyme that catalyzes the removal of fibrin. Plasmin is derived 
from plasminogen, an inert protein precursor that can be activated by 
tissue plasminogen activator. Streptokinase, urokinase, and tissue 
plasminogen activator are drugs that activate plasminogen and lead to the 
dissolution of clots (Waisman DM, Plasminogen: Structure, Activation and 
Regulation, 2003) 
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2.1.5 Synthesis of blood-clotting proteins 
Almost every clotting protein is synthesized in the liver except FVIII which 
is additionally produced in a large number of other tissues (Wion et 1985). 
FIX, FX, prothrombin, FVII, protein C and protein S are synthesized in a 
precursor form and need vitamin K to complete their synthesis. 
 
Table 1: Concentrations of coagulation factors required for normal hemostasis. With the 
exception of fibrinogen, factor levels are usually reported as percentages of the 
concentrations present in plasma pooled from normal individuals. Tissue factor is not 
present in plasma and cannot be quantified in patients.                                                      
Source: Tollefsen DM, Washington University in St. Louis: 
http://tollefsen.wustl.edu/projects/coagulation/coagulation.html 
 
 
2.2 Factor VIII (FVIII) 
It was proven in 1840 that a bleeding disorder inherited within families, 
known as hemophilia, is due to a factor in the blood by correction of the 
bleeding defect by transfusion of whole blood. Decades later in 1937 a 
factor was shown to be effective in accelerating the coagulation process: 
antihemophilic globulin, today better known as factor VIII (FVIII). 
 
FVIII is a glycoprotein, which is synthesized and released into the 
circulation by the liver. Additionally FVIII mRNA was found in spleen and 
other tissues but they are not yet completely identified (Jacquemin et al; 
2006). After synthesis FVIII moves to the lumen of endoplasmatic 
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rediculum and is bound to proteins that regulate secretion. At the 
endoplasmatic rediculum cleavage of the signal peptide and addition of 
oligosaccharides occur. The chaperon proteins calinexin and calreticulin 
enhance secretion and degradation. 
 
The primary translational product of FVIII is inefficiently transported from 
the endoplasmic reticulum to the Golgi apparatus (Dorner et al 1987), 
where several changes take place. For instance the posttranslational 
addition of sulphates to tyrosine residues that have a major impact on the 
procoagulant activity of FVIII and its interaction with von Willebrand Factor. 
 
The FVIII gene was first discovered in 1984. It is located on the X-
chromosome (Gitschier et al 1984), has a size of 186 kDa and is divided 
into 26 exons (Hoyer, 1994; Bi et al, 1995, Thompson 2003). The factor 
VIII protein consists of 2332 amino acids, arranged in this domain order 
A1-A2-B-A3-C1-C2 (Thompson 2003). Crystal structures of activated FVIII 
have been recently solved at just under 4 Angstrom resolution (Ngo et al 
2008, Shen et al 2008). 
 
 
Figure 2: Crystal structure of FVIII: Shen et al 2008: The tertiary structure and domain 
organization of coagulation factor VIII. Blood 2008 Feb 1; 111(3):1240-7 
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Before the release into  the circulation, the protein is proteolytically 
cleaved into a heavy chain, consisting of A1-A2-B domain and a light 
chain, consisting of A3-C1-C2 domain. (Vehar et al, 1984) The light chain 
contains the binding site for von Willebrand factor. Both parts of the 
heterodimer are kept together via a divalent Ca2+ ion. 
Upon activation by thrombin (Factor IIa), FVIII dissociates from the 
complex with VWF to interact with Factor IXa and phospholipids. It is a 
cofactor to Factor IXa in the activation of Factor X to Factor Xa, which, in 
turn activates more thrombin together with its cofactor Factor Va. 
Thrombin cleaves fibrinogen into fibrin which polymerizes and cross-links 
(using Factor XIII) into a blood clot. No longer protected by VWF, activated 
FVIII is proteolytically inactivated in the process and quickly cleared from 
the blood stream (Colman et al, Hemostasis and Thrombosis 2001). 
 
 
Figure 3: Factor VIII. Structural domains of human factor VIII. Adapted from Stoilova-
McPhie S, Villoutreix BO, Mertens K, et al. 3-Dimensional structure of membrane-bound 
coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional 
density map derived by electron crystallography. Blood 2002 Feb 15; 99(4): 1215-23. 
Roberts HR, Hoffman M. Hemophilia A and B. In: Beutler E, Lichtman MA, Coller BS, et 
al, eds. Williams Hematology. 6th ed. NY: McGraw-Hill; 2001:1639-1657. Roberts HR. 
Thoughts on the mechanism of action of F VIIa. Presented at: 2nd symposium on New 
Aspects of Haemophilia Treatment. 1991; Copenhagen, Denmark. 
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2.3 Hemophilia A 
Hemophilia A is a bleeding disorder that is characterized by a deficiency in 
factor VIII clotting activity that is due to the lack or an insufficient amount of 
the clotting protein FVIII in the blood circulation. The cause of the disease 
is a genetic defect of the X-chromosome, which can be either inherited (or 
a spontaneous mutation. 80% of all Hemophilia patients are suffering from 
a FVIII deficiency.  
 
 
Figure 4: The gene for hemophilia is passed from mothers (XX) to sons (XY) via the X 
chromosome. A son who inherits a defective X chromosome from his mother does not 
have a healthy X chromosome to rely on the way daughters (XX) do.                                                           
Source: http://www.humanillnesses.com/original/Gas-Hep/Hemophilia.html 
 
Due to the fact that the FVIII gene is located on the X-chromosome and is 
a recessive hereditary disease, it affects mainly male individuals. It’s 
affecting about 1 of 5000-10000 men (Aledort et al, Textbook of 
Hemophilia 2005). 
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2.3.1 History of hemophilia A 
The first recognition of excessive and unexplained bleeding was made in 
the Talmud, which is a collection of Jewish Rabbinical writings from the 2nd 
century AD (Talmud, Tractate Yevamot 64b). It was described that male 
babies did not have to be circumcised if two brothers already died from 
that procedure. 
 
The Arabian physician Albucasis (12th century AD) wrote of males in a 
particular village, who had died of uncontrollable bleeding (Skinner 2001). 
The word “hemophilia”, from the Greek haima “blood” and philia “to love” 
(Harper D, Online Etymology Dictionary), first appeared in 1828 at the 
University of Zurich in a description of a bleeding disorder condition 
(Canadian Hemophilia Society, History of Hemophilia). 
 
One of the most famous carriers of Hemophilia A was Queen Victoria of 
England (1837-1901) who passed the disease on to several royal families 
in Europe, including the Spanish, German and Russian Royals. Because 
of this, Hemophilia has often been called the “Royal disease” (Potts 1999) 
 
2.3.2 Symptoms and diagnosis of hemophilia A 
People with untreated hemophilia A are suffering from prolonged bleeding 
after injuries, tooth extractions or surgery, or having renewed bleeding 
after the initial bleeding already has stopped( Kessler & Mariani 2006). 
Muscle hematomas or inter-cranial bleeding can occur even 4 to 5 days 
after the injury. Other typical symptom for hemophilia A patients are 
spontaneous bleeding events, especially in the joints like knees, ankles 
and elbows. 
 
The time of diagnosis and the frequency of the bleeding episodes depend 
mainly on the severity of disease. However, the bleeding events are more 
frequent in childhood and adolescence than in adulthood. This could be 
due to physical activity levels as well as vulnerability during more rapid 
growth. 
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3 severities of hemophilia A are: 
 
Severe hemophilia A: 
We are talking of severe hemophilia A when the FVIII clotting activity is 
below 1% of normal. The diagnosis for people with severe hemophilia A 
happens most of the time during their first year of life. Sometimes they 
already have extra- or intracranial bleedings following birth. In some 
babies, hemophilia is suspected immediately when a routine circumcision 
results in unusually heavy bleeding. Small children are at particular risk 
because they frequently fall and may bleed into the soft tissue of their 
arms and legs. These small bleeds result in bruising and noticeable lumps 
but do not usually require treatment. As a child becomes more active, 
bleeding may occur into the muscles, a much more painful and debilitating 
situation. These muscle bleeds result in pain and pressure on the nerves 
in the area of the bleed. Damage to nerves can cause numbness and 
decreased ability to use the injured limb. Patients do have in average 2-5 
spontaneous bleeding events per month. Though the joints are the 
common site where bleeding occurs, it happens on other sites as well like 
in kidneys, gastrointestinal tract and brain. Without treatment patients 
suffer from prolonged bleeding episodes or excessive pain and swelling 
from minor injuries (Aledort et al, Textbook of Hemophilia 2005). 
 
Moderately severe hemophilia A: 
Patients with moderately severe hemophilia A do have a FVIII clotting 
activity between 1 and 5 % of normal. With this level of functional FVIII, 
spontaneous bleeding is rare, but a prolonged bleeding after a relatively 
minor trauma is common. Usually it is diagnosed before the age of 5 or 6. 
Bleeding episodes occur between once a month to once a year. The signs 
and the symptoms for bleeding are the same as for severe hemophilia A 
(Aledort et al, Textbook of Hemophilia 2005). 
 
Mild hemophilia A 
Individuals with mild hemophilia A do have a FVIII clotting activity between 
6 and 35% of normal. Abnormal bleeding occurs with surgery, tooth 
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extractions and major injuries. Patients never have spontaneous 
bleedings. Therefore, they are often not diagnosed until later in life when 
they have for example a surgery or a major trauma. Bleeding episodes 
occur between once a year and once every ten years (Aledort et al, 
Textbook of Hemophilia 2005). 
 
Although female carriers of hemophilia A do not have the disease, they 
could have a FVIII clotting activity below 35% which could lead to 
symptoms like in male patients with mild hemophilia A. Moreover it was 
shown, that female carriers with FVIII activity between 35% and 60% may 
have subtle abnormal bleeding (Plug et al 2006). 
Table 2: Symptoms related to severity of untreated hemophilia A. Adopted from: Aledort et 
al, Textbook of Hemophilia 2005 
 
 
2.3.3 Molecular genetics of hemophilia A 
There are several pathologic allelic variants of the factor VIII gene that 
lead to hemophilia A. First of all a gene inversion through recombination 
between a sequence located within intron 22 with one end of the two 
additional copies of homologues sequence near the telomere of the long 
arm of the X-chromosome (Bagnall et al 2006). This mutation is the cause 
for about 45% of all severe hemophilia A cases (Kaufman et al 2006). 
 
Severity 
Factor VIII 
clotting 
activity
Symptoms 
Usual Age 
of 
Diagnosis 
Severe <1% Frequent spontaneous bleeding; abnormal bleeding 
1st year of 
life 
Moderately
severe 
Mild >6%-35% 
No spontaneous bleeding; 
abnormal bleeding after major 
injuries, surgery, or tooth 
extractions 
Often later 
in life 
1%-5% 
Spontaneous bleeding is rare; 
abnormal bleeding after minor 
injuries, surgery, or tooth 
extractions 
Before age 
5-6 years 
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A different recurrent inversion occurs between a 1-kb sequence in intron 1 
that is repeated in the reverse orientation to the factor VIII gene (Bagnall 
et al 2002); this type occurs in up to 3% of families with severe hemophilia 
A. The rest of the mutations cover the entire spectrum: a complete or 
partial deletion of FVIII, large insertions, sequence duplications, frame 
shifts, splice junction alterations, nonsense mutations and missense 
mutations. The resulting gene product goes from total absence of 
detectable protein (majority of individuals with severe hemophilia A) to 
those with normal levels of a dysfunctional protein (Aledort et al, Textbook 
of Hemophilia 2005). 
 
2.3.4 Treatment of hemophilia A patients 
Before 1960, patients with severe hemophilia A had a life expectancy of 
only 25 years. But this has been changed over the last four decades 
through advancements in treatment that permitted a near-normal lifestyle 
and life span for many individuals with hemophilia (Darby et al 2007). 
Nowadays hemophilia A patients in the western world are treated by 
administering a replacement therapy with FVIII concentrates which could 
either be plasma-derived or recombinant. In the 1970s the introduction of 
factor VIII concentrates revolutionized the therapy. It allowed treatment at 
home and largely replaced the need for transfusion of whole blood or 
plasma in the hospital (Pool et al 1964). But the other side of the coin was 
infection with hepatitis and HIV from products made from pooled plasma. 
In the early 1980s about 70% of hemophiliac patients were infected with 
HIV. Therefore, a virucidal treatment of plasma-derived FVIII concentrates 
has been established, which lower the risk of HIV transmission since 1985 
and for hepatitis B and C since 1990. Moreover a recombinant FVIII 
concentrate was developed, which today provide no content of any human 
or animal derived proteins (Aledort et al, Textbook of Hemophilia 2005). 
 
Factor VIII is given by direct injection either on demand or prophylactic. On 
demand treatment is just for individuals with mild or moderately severe 
hemophilia. FVIII is administered when bleeding occurs in order to stop the 
bleeding as soon as possible and prevent further damage from bleeding. 
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People with severe hemophilia are receiving a prophylactic treatment. It is 
a regular continuous treatment with FVIII concentrate to keep the level of 
the clotting factor in the blood high enough to prevent spontaneous 
bleeding and decrease the number of bleeding episodes. Prophylactic 
infusion almost completely eliminates joint bleeding and therefore greatly 
decrease chronic joint disease. The benefit of prophylactic treatment for 
people with severe hemophilia is not questioned, but there is still a 
controversy when to start with. The age when a child first experiences a 
joint bleeding can vary greatly. Moreover a prophylactic treatment is very 
expensive and only patients in the western world can afford the costs of a 
treatment (Aledort et al, Textbook of Hemophilia 2005). 
 
Although most individuals with hemophilia can use replacement products 
repeatedly without problems, one of the most problematic complications of 
treatment is the development of inhibitors to FVIII (Ehrenforth et al 1992 ; 
Hoyer et al 1995). Inhibitors are typically IgG antibodies against FVIII that 
neutralize the coagulant effects of replacement therapy. Inhibitors to FVIII 
occur approximately in 20-30% of severe hemophilia A patients. 
Management for patients who developed inhibitors includes the 
eradication of circulating FVIII neutralizing antibody via immune tolerance 
induction (ITI). The first reports on immune tolerance induction as 
treatment of hemophiliacs, were proposed by Brackmann and Gromsen in 
1977 (Brackman et al 1977). This procedure is only effective in 60-80% of 
the patients (DiMichele 2000). The other patients have to take bypassing 
products such as Feiba or FVIIa.  
 
2.4 Extension of factor VIII half-life 
For patients with prophylactic treatment it is necessary to receive about 3 
times a week FVIII concentrate injections to keep the level of FVIII in blood 
high enough to prevent spontaneous bleeding. This is due to the half-life 
of an average of 12 hours of FVIII in circulating blood. Baxter Innovations 
GmbH is currently trying to improve this procedure by elongating the half-
life of FVIII to make the therapy more convenient for the patients.  
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Figure 5: The idealized pharmacokinetic profile of an unmodified drug compound (grey) 
and its optimized second-generation version (blue): Rottensteiner HP, Baxter BioScience, 
unpublished 
 
Injection of an unmodified drug lead to the need of more injections. 
Moreover you end up with too high concentration in the blood at the time 
of injection and too low concentration after a relative quick period of time. 
In theory an engineered compound requires fewer injections and provides 
for a better match within he therapeutic window (Figure 5).  
 
Baxter Innovations GmbH is trying to elongate the half-life of FVIII by 
chemical modification with polyethylene glycol (PEG) of rFVIII itself using 
ADVATE or rVWF, which serves as the carrier molecule of FVIII. 
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2.5 Polyethylene glycol (PEG) 
Many biopharmaceuticals especially proteins and peptides have typically 
problems like a short circulating half-life, immunogenicity, proteolytic 
degradation and low solubility. There are several ways to come over this 
problem. For instance manipulation of the amino acid sequence to 
decrease immunogenicity and proteolytic cleavage, fusion or conjugation 
to immunglobulins and serum proteins, incorporation into drug delivery 
vehicles for protection and slow release, and conjugation to natural or 
synthetic polymers (MJ Roberts et al 2002). 
 
Polyethylene glycol (PEG) is a highly investigated polymer for the covalent 
modification of biological macromolecules and surfaces for many 
pharmaceutical and biotechnical applications. In the last years the 
scientific community has become quite familiar with the improved 
pharmacological and biological properties that are associated with the 
covalent attachment of PEG (PEGylation) to therapeutically useful 
polypeptides (MJ Roberts et al 2002). 
 
For example, PEGylation can shield antigenic epitopes of the polypeptide 
and therefore reduce reticuloendothelial (RES) clearance and recognition 
by the immune system. During the last years it has been realized that the 
chemistry and the quality of the used PEG reagents play an important role 
for peptide and protein modification. Therefore a second generation of 
PEG chemistry has been established to avoid the problems that are 
associated with PEG-protein products that were developed using the first 
generation of PEG chemistry. Those problems were deactivated PEG 
impurities, restriction to low molecular weight mPEG, unstable linkages 
and lack of selectivity in modification (MJ Roberts et al 2002). 
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2.5.1 Properties of polyethylene glycol 
In its most common form polyethylene glycol is a linear or branched 
polyether terminated with hydroxyl groups and having the general 
structure: 
 
HO - (CH2-CH2-O)n – CH2 CH2 – OH 
 
PEG is synthesized by anionic ring opening polymerization of ethylene 
oxide starting with a nucleophilic attack of a hydroxide ion on the expoxide 
ring. An important aspect of PEGylation is the incorporation of various 
PEG functional groups that are used to attach the PEG to the peptide or 
protein. Most useful for polypeptide modification is monomethoxy PEG, 
mPEG, having the general structure: 
 
CH3O - (CH2-CH2-O)n – CH2 CH2 – OH 
 
Compared with other polymers, PEG has a relatively narrow polydispersity 
in the range of 1.01 for low molecular weight PEGs (<5kDa) to 1.1 for high 
molecular weight PEGs (>50kDa). It is calculated by dividing the weight 
average molecular weight with the number average molecular weight. 
Polydispersity indicates the distribution of individual molecular masses in a 
batch of polymers (MJ Roberts et al 2002). 
 
PEG is soluble in both aqueous and organic solutions, which makes it 
suitable for end group derivatization and chemical conjugation to biological 
molecules under mild physiological conditions. 
 
Another important property of PEG is the binding of 2-3 water molecules 
per ethylene in solution. Therefore and because of the high flexibility of the 
backbone chain, PEG acts if it were 5-10 times as large as a soluble 
protein of comparable molecular weight. These factors have been 
suggested as the reason that PEG exhibits the ability to precipitate 
proteins (Polson 1977), exclude proteins and cells from surfaces 
(Gombotz 1992), reduce immunogenicity and antigenicity (Abuchowski 
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1977) and prevent degradation by mammalian cells and enzymes 
(Working 1997). 
 
PEG clearance occurs without structural change and depends on the 
molecular weight. PEGs with a size below 20kDa get cleared through 
urine, PEGs higher than 20kDa get cleared more slowly in the urine and 
feces (MJ Roberts et al 2002).  
 
It has been shown that low molecular weight oligomers of PEG (<400Da) 
degraded in vivo to toxic metabolites, but lack of toxicity with a molecular 
weight above 1000 Da has been revealed over many years of use in 
foods, cosmetics and pharmaceuticals (Working 1997). 
 
2.5.2 Chemistry of PEGylation 
For the coupling reaction between the PEG and the molecule of interest, it 
is necessary to activate PEG by making a derivative of the PEG having a 
functional group at one or both termini. The choice which functional group 
to take is depending on the reactive groups on the molecule that will be 
coupled.  
 
HO - (CH2-CH2-O)n – X    or  MeO - (CH2-CH2-O)n – X  
X: functional group for coupling to protein 
 
The most common route for PEG conjugation of proteins has been to 
activate the PEG with functional groups suitable for reactions with lysine 
and N-terminal amino acid groups. 
 
The monofunctionality of methoxyPEG makes it particularly suitable for 
protein and peptide modification because it yields reactive PEGs that do 
not produce cross-linked polypeptides, as long as diol PEG has been 
removed (MJ Roberts et al 2002). 
 
  Introduction 
  28/89 
2.5.3 PEG structures 
Branched structures of the PEG have been proven to be very useful in 
addition to the linear structures when you PEGylate a protein or a peptide. 
For example a branched PEG attached to a protein acts much larger than 
a corresponding linear mPEG of the same molecular weight (Yamasaki 
1988). This structure of PEG also has the advantage of adding two PEG 
chains per attachment site on the protein, therefore reducing the chance of 
protein inactivation. Furthermore, this structure is more effective in 
protecting proteins from proteolysis, reducing antigenicity and reducing 
immunogenicity (Veronese 1997). 
 
2.5.4 PEGylation of FVIII 
Baxter Innovations GmbH has chosen to do the PEGylation with a 
branched stable PEG reagent to chemically modify FVIII in order to 
increase its half-life in circulating blood. 
 
 
OCH2CH2H3C NH C O
O
OCH2CH2CH2 C O
O
N
O
O
OCH2CH2H3C NH C O
O
n
n
 
Figure 6: Structure of Nektars stable PEG reagent: PEG2ruNHS 20K. Nektar 
Therapeutics, San Carlos USA 
 
The structure of the stable PEGylation reagent (PEG2ruNHS20K) is 
shown in Figure 6. The two PEG chains are connected to a glycerol 
backbone via a reversed urethane segment. In addition an active N-
hydroxsuccinimide (NHS) ester is linked to the glycerol residue in position 
2 via a propanoxy group. The NHS ester can react with primary amino 
groups (N-terminus and ε-amino groups of lysines) to form a stable amide 
bond. 
 
In Figure 7 the structure of the conjugate after PEGylation with the stable 
PEGylation reagent is shown. 
  Introduction 
  29/89 
 
Figure 7: Structure of the conjugate. Siekmann J, Baxter BioScience, unpublished 
 
2.6 Anti-PEG antibodies 
To evaluate the incidence of anti-PEG antibodies within a normal, healthy 
human population, Armstrong et al analyzed 250 plasma samples of 
normal donors (Armstrong JK et al, ASH 2003) employing the methods as 
described by Fisher et al. 25.2% of samples were positive for IgG and/or 
IgM, of which 18.4% showed IgG binding only, 3.6% IgM only, and 3.2% 
both. A further study performed in ALL subjects receiving PEG-
Asparaginase demonstrated the development of anti-PEG antibodies 
(Armstrong JK et al, ASH 2006): 9 of 15 subjects who showed 
undetectable asparaginase activity tested positive by serology and 13 
when using the flow cytometry, whereas a cohort of 13 subjects with 
normal sustained levels of asparaginase activity after treatment did not 
develop anti-PEG antibodies. In approximately one third of the patients 
having developed anti-PEG antibodies, rapid clearance of PEG-
Asparaginase rendered treatment ineffective. No relationship was 
observed between the presence of anti-PEG antibodies and serum 
asparaginase activity for patients treated with unmodified asparaginase. 
 
These findings of anti-PEG antibodies raise the question whether 
1. the presence of anti-PEG antibodies may alter the pharmacokinetic 
profile of the pegylated conjugate and eventually render treatment 
less effective or ineffective, necessitating a modification of dosing 
recommendations; 
2. pegylated coagulation factors induce anti-PEG antibodies leading to 
a less effective treatment as mentioned in 1). 
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2.7 Objectives of the diploma project 
The aim of my project was to establish an anti-PEG antibody detection 
assay. The assay had to be stable, reproducible, reliable, accurate and 
specific for anti-PEG antibodies in order to comply with quality 
requirements. Once the test was established it was used to monitor the 
development of anti-PEG antibodies in disease models in mouse and rat 
during preclinical studies of new drug candidates that are currently 
developed by Baxter Innovations GmbH as well as for screening healthy 
human blood donors for the potential presence of “natural” anti-PEG 
antibodies. This study in healthy blood donors provides important 
information for the screening of patients to be included in clinical studies of 
the new PEGylated protein drug candidates. 
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3. Material and Methods 
3.1 Material 
3.1.1 Reagents 
Tentagel M NH2     Rapp Polymere 
        Thübingen, Germany 
 
D-PBS       Invitrogen 
        Carlsbad, USA 
 
Anti-PEG monoclonal IgM     Academia Sinica 
(Clone Number: AGP3)    Nanking, Taiwan 
 
Anti-PEG monoclonal IgG1     Academia Sinica 
(Clone Number: E11)     Nanking, Taiwan 
 
Anti-PEG rabbit monoclonal IgG   Epitomics 
(Clone ID:PEG-B-47)     Burlingame, USA 
 
Anti-PEG/Albumin from rabbit, protein A purified Baxter BioScience 
        Deerfield, USA 
 
Goat anti-mouse IgM-RPE, Human adsorbed Southern Biotech 
        Birmingham, USA 
 
Goat anti-mouse IgG1     Southern Biotech 
        Birmingham, USA 
 
Goat anti-rat IgG-RPE     Southern Biotech 
        Birmingham, USA 
 
PEG2ruNHS 20K     Nektar Therapeutics 
        San Carlos, USA 
  Material and Methods 
  32/89 
HEPES       Merck 
        Darmstadt, Germany 
 
NaCl       Merck 
        Darmstadt, Germany 
 
HCl       Merck 
        Darmstadt, Germany 
 
Glycine       Merck 
        Darmstadt, Germany 
 
WFI       Baxter BioScience 
        Deerfield, USA 
 
APC Conjugation KIT     AbD Serotec 
        Oxford, UK 
 
3.1.2 Plastic & Consumables 
Pipette tips ( 20, 200, 1000µl)    Eppendorf 
        Hamburg, Germany 
 
Combitips      Eppendorf 
        Hamburg, Germany 
 
Tubes 30ml      Sterilin 
        Hounslow, UK 
         
Polypropylene tubes 1,4ml    Micronic 
        Lelystad, Netherlands 
 
Polysterene round bottom, 5ml   Becton Dickinson 
        Franklin Lakes, USA 
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CellTrics disposable filter, 30µm   Partec 
        Görlitz, Germany 
3.1.3 Buffers 
Buffer A       50mM HEPES 
        100mM NaCl 
        WFI 
        pH: 7,6 
 
Buffer B       20mM HEPES 
        150mM NaCl 
        WFI 
        pH: 7,4 
 
2mM HCl        
 
01M Glycin solution      
 
3.1.4 Equipment 
Pipettes (0,5-10µl, 10-100µl, 100-1000µl)  Eppendorf 
        Hamburg, Germany 
 
Multipipette      Eppendorf 
        Hamburg, Germany 
 
Stuart Vortex Mixer     SciLabware Limited 
        Staffordshire, UK 
 
Lab-scale      Sartorius 
        Göttingen, Germany 
 
FACS Calibur      Becton Dickinson 
        Franklin Lakes, USA 
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Heraeus Centrifuge     DJB Labcare Ltd 
        Buckinghamshire, UK 
 
Microcentrifuge      Eppendorf 
        Hamburg, Germany 
 
Ultrasonic bath      Elma 
        Singen, Germany 
 
Particle counter      Beckman Coulter 
        Fullerton, USA 
 
Boxer Gas pump     Uno International Ltd. 
        London, UK 
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3.2 Methods 
3.2.1 Flow Cytometry 
Flow Cytometry is a powerful technique for the analyses of multiple 
parameters of individual cells within heterogeneous populations. This 
technique can be used for many applications, for instance 
immunophenotyping, ploidy analyses, cell counting or GFP expression 
analyses. The basic principle of this approach is the emerging light after 
cells pass a laser beam that can be gathered and give rise about cell 
characteristics such as size, complexity, phenotype and health 
(Langobardi Givan 2001). 
 
Instrument Overview 
• Fluidic system: presents the sample to the interrogation point and 
takes away the waste. For accurate data collection the particles or 
cells have to pass the laser beam one by one. For this purpose the 
sample stream is injected into a flowing stream of sheath fluid or 
saline solution. The sample stream gets compressed to one cell in 
diameter. This process is called hydrodynamic focusing. 
• Laser: The light source for scatter and fluorescence 
• Optics: gathering and direct the light 
• Detector: receive the light 
• Electronics and peripheral computer system: convert signals from 
the detectors into digital data and do the analyses. 
 
The interrogation point is the heart of the system. It is the point where the 
laser and the sample intersect and where the optics collect the resulting 
scatter and fluorescence. 
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Electronics  
 
Figure 8: Overview of a flow cytometric system. Invitrogen: Tutorials on fluorescence and 
flow cytometry. http://www.invitrogen.com/site/us/en/home/support/Tutorials.reg.at.html  
 
When a cell pass the laser beam it scatters light at all angles. 
 
Forward Scatter 
The forward scatter is the amount of light that is scattered in the forward 
direction as laser strikes the cell. The scattered light is collected by a 
detector that converts intensity into a voltage pulse. The magnitude of this 
pulse is proportional to the size of the cell and can therefore be used to 
quantify that parameter. Small cells produce a small amount of forward 
scatter, large cells a large amount. An obscuration bar is placed in front of 
the detector to prevent any of the intense laser light reaching the detector. 
When plotting the data on a histogram, smaller cells appear left, bigger 
cells right (Langobardi Givan 2001). 
 
Side Scatter 
The light scattering at larger angles, for example to the side, is caused by 
granularity and structural complexity inside the cell. Side scattered light is 
focused through a lens system and collected by a detector, usually located 
Laser 
Fluidics 
Detectors 
Optics 
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90 degree from the laser’s path. Recording of the data is the same as for 
forward scatter (Langobardi Givan 2001). 
 
Fluorescence 
The term fluorescence is used to describe the excitation of a fluorophore 
to a higher energy level followed be the return of that fluorophore to the 
ground state with the emission of light. 
 
 
Figure 9: Principle of fluorescence: a fluorophore that can absorb blue light. Because the 
photonic energy is related to the wavelength there is a difference in the colour light that is 
absorbed to that which is emitted.                                                                                          
Source: Centre for synaptic plasticity, University of Bristol. 
http://www.bristol.ac.uk/synaptic/info/imaging/imaging_1.htm  
 
One of the major applications in flow cytometry is to study cellular 
characteristics by fluorophore-labeled antibodies that bind to cell specific 
proteins. When a cell passes through the laser beam with the right 
wavelength, the fluorophore gets excited and emits light at a specific 
wavelength that gets collected by a detector. The fluorescent light coming 
from labeled cells as they pass the laser travels along the same way as 
the side scatter signal. After passing a series of filters and mirrors, the light 
with the right wavelength is delivered to the appropriate detectors. There 
the signal is translated to a voltage pulse that is proportional to the amount 
of fluorescence emitted, similar to forward- and side scatter (Langobardi 
Givan 2001). 
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Gating 
One of the major analyses tools in flow cytometry is gating. This tool 
enables us to direct the analyses software to consider only specific cells or 
particles for further analyses (Langobardi Givan 2001). 
 
3.2.2 Chemical modification of TentaGel M NH2 with a branched 
stable PEG reagent 
TentaGel M NH2 Beads (capacity: 0.24 mmol/g) were provided by Rapp 
Polymere. The primary amino group of the PEG chain was chemically 
modified by use of a branched PEGylation reagent PEG2ruNHS 20K, 
containing an active N-hydroxysuccinimide (NHS) group. 450 mg TentaGel 
M NH2 Beads were suspended in 20 ml Buffer A. Then the suspension 
was centrifuged for 30 min (2800 RCF). The supernatant was discarded 
and the remaining beads were suspended again in 20 ml Buffer A. The 
suspension was gently shaken for five minutes and placed in an ultrasonic 
bath for 30 sec to avoid aggregates. Then the washing procedure was 
repeated. Finally the pH of the suspension was controlled. Then the 
PEGylation reagent was dissolved in 2 mM HCl (75 mg/ml) and added to 
the beads suspension to give a final concentration of 0.6 mg PEG 
reagent/mg TentaGel. The PEGylation reaction was performed for 2 h at 
room temperature under gentle shaking. Subsequently the reaction was 
terminated by addition of a 0.1M Glycine solution (final concentration: 
0.01M). This solution was gently shaken again for 1 h at room 
temperature. Then the PEGylated beads were centrifuged and 
resuspended with Buffer B as described above. This washing procedure 
was performed three times. Finally the beads suspension was 
resuspended in Buffer B and lyophilized. 
 
3.2.3 Anti-PEG antibody detection assay 
Bead preparation 
Anti- polyethylene glycol (PEG) antibodies were detected by TentaGel M 
NH2 microspheres. Those polystyrene beads (diameter: 10 µM) are 
grafted with PEG and were additionally conjugated with branched PEG 
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reagent. After conjugation reaction the beads were lyophilized. and stored 
at 4°C. 
 
Before using the beads they had to get reconstituted in PBS and left for at 
least 1 hour to have time for swelling. The beads were washed with 20ml 
PBS, centrifuged at 300g for 5 minutes and the supernatant was 
discarded. This step was one time repeated and the pellet was 
reconstituted with an appropriate amount of PBS to get a 1% solution. 
Short sonification and filtration of the bead-solution should prevent any 
formation of clumps. The beads were counted and diluted if required to get 
a final concentration of about 2x106/ml. 
 
Sample preparation and anti-PEG antibody detection reaction 
The blood samples taken from humans or animals were centrifuged for 10 
minutes at 1100g and once more for 20 minutes in order to isolate the 
plasma. Supernatant was collected and was ready for further use in the 
detection assay. 
 
We filled 25 µl of the bead solution together with 25µl of the plasma 
samples into micronic tubes and vortex them. Incubation step occurred at 
room temperature for 30 minutes. The reaction was stopped by filling 1ml 
PBS to the solution. Now we centrifuged at 200g for 2 minutes and 
evacuated the supernatant till 50µl are left in the tube. This washing step 
was repeated once more. 
To detect antibodies that were bound to the surface of the Tentagel beads 
we took secondary antibodies labeled with fluorochromes that were 
directed against those primary antibodies. The secondary antibodies were 
diluted 1:32 with PBS and 5µl of each antibody was given to the micronic 
tubes. The tubes were vortexed and the incubation was running for 30 
minutes at room temperature in the dark. The reaction was stopped again 
by filling 1ml PBS to the solution. Now we centrifuged at 200g for 2 
minutes and evacuated the supernatant till 50µl are left in the tube. This 
washing step was repeated once more and the pellet was reconstituted in 
50µl PBS. 
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The samples were now analyzed by flow cytometry. 
 
 
Figure 10 : Overview of the anti-PEG antibody detection assay 
 
All experiments that were done to detect anti-PEG antibodies were done 
with this procedure if not otherwise indicated. 
 
3.2.4 Experimental set ups to establish the anti-PEG antibody 
detection assay 
Establishing the assay 
The first experiments were done using a protein A purified IgG antibody 
from rabbits that were treated before with PEG-FVIII. TentaGel Beads 
from Rapp polymere without additional PEGylation were used in this 
experiment. As negative control unstained beads and beads incubated 
with the secondary antibody were used. 
 
Titration of the beads 
To see whether the concentration of the beads has an influence on the 
detection of the anti-PEG antibodies, a titration of the beads was done. 
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The bead solution was serially diluted with PBS and different dilutions 
were tested using the rabbit anti-PEG antibody in 1:2 dilution with PBS as 
a positive control. As negative control unstained beads and beads 
incubated with the secondary antibody only were used. 
 
Antibody titration 
Commercially available monoclonal murine IgG and IgM anti-PEG 
antibodies were ordered to use them in future as a positive control to 
check for proper operation of the assay. A titration of each primary and 
secondary antibody was done to find out the best dilution. Lowering the 
concentration of the antibody to a point that would be necessary to see a 
positive signal, enabled us to exclude unspecific binding on the one hand, 
and on the other hand reduce the costs of each experiment. Each 
antibody was diluted with PBS and different concentrations were tested. 
 
TentaGel vs. TentaGel with branched PEG 
To see if the additional PEGylation of the TentaGel beads had an 
influence on the assay, a comparison between both bead types was done. 
For this purpose, we used mice plasma samples that had been tested 
positive for IgM anti-PEG antibodies before. The plasma samples were 
diluted with PBS 1:20 and were tested with both bead types.  
 
Storage and stability tests 
Another important issue was to ensure that the beads used for analyses 
are stable, first of all in terms of PEGylation, and how to store them best 
without destabilizing. To encounter that question, one lot of the beads was 
stored under 4°C and tested several times during a time period of 4 
weeks. 
In addition three different batches of beads with additional PEGylation 
were produced and lyophilized. Every batch was stored under 3 different 
conditions, namely 4°C, room temperature and 37°C. Analyses were done 
shortly after production and after 4 weeks of storing. 
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A murine monoclonal IgM anti-PEG antibody was used as positive control, 
the unstained beads and the beads incubated with secondary antibody 
only were used as negative control. 
Competition Assay 
To see whether the test is specific for anti-PEG antibodies a competition 
assay was established. The positive control was divided in two aliquots: 
One aliquot was pre-incubated with 5µl of soluble PEG (wt 200) in different 
dilutions for 30 minutes at room temperature, the other aliquot was 
incubated with 5µl PBS. The dilutions of the soluble PEG were done 
geometrically with PBS. A monoclonal rabbit IgG anti-PEG antibody was 
used as a positive control. As negative control the unstained beads and 
the beads incubated with the secondary antibody were taken. 
 
3.2.5 Cut off experiments in mouse 
The aim of this experiment was to define the cut off in mice that was 
needed to distinguish between positive and negative plasma samples. For 
this purpose blood samples from 53 naïve mice, which means they had no 
treatment with polyethylene glycol, were taken and plasma analyzed with 
the anti-PEG antibody detection assay. The plasma samples were pre-
diluted with PBS to have an end concentration of 1:20, 1:40, 1:80 and 
1:160. The murine monoclonal antibodies against PEG were used as 
positive control, unstained beads and beads incubated with secondary 
antibody only were used as negative control. 
 
The results obtained from the 1:20 dilution were taken to define the cut off 
by calculating the 95% percentile using the software program SPSS 
(SPSS Inc., Chicago, USA). 
 
3.2.6 Statistical method to define the cut off: 95 % percentile 
A percentile is the value of a variable below which a certain percent of 
observations falls. The 95th percentile is the value (or score) below which 
95 percent of the observations are found. The term percentile and the 
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related term percentile rank are often used in descriptive statistics as well 
as in the reporting of scores from norm-referenced tests. 
SPSS is using following method to estimate the value, vp, of the pth 
percentile of an ascending ordered dataset containing N elements with 
values v1,v2,...,vN; 
 
n is then split into its integer component, k and decimal component, d, 
such that n = k + d 
If N = 1, the value for the percentile, vp, is the only member of the dataset, 
v1. 
Else If k = N, then vp = vk − 1 + d(vk − vk − 1). 
Else (1 < k < N) then vp = vk + d(vk + 1 − vk). 
(David Lane, “Percentiles” 2007) 
 
3.2.7 Monitoring of potential anti-PEG antibody development in mice 
treated with PEGylated proteins 
In the course of the factor VIII Half-life (FVIII-HL) project (extension of the 
factor VIII half-life) another important protein within the coagulation 
process was PEGylated: von Willebrand factor (VWF). VWF is the carrier 
molecule of FVIII. Several studies have been done to compare the 
immunogenicity of recombinant von Willebrand factor (rVWF) and 
PEGylated rVWF. In all experiments, humanized E17 mice were used. 
 
Humanized E17 mice 
MHC-class II molecules are not only crucial for the regulation of adaptive 
immune responses against protein antigens but are also essential for 
shaping the CD4+ T-cell repertoire in the thymus (von Boehmer 2003). 
Structural differences between the murine and the human MHC-class II 
complex belong to the major limitations in the use of conventional murine 
disease models for dissecting immune responses to human protein 
antigens. In view of these limitations, considerable efforts have been put 
into the development of murine disease models that carry transgens for 
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human MHC-class II on the background of a knockout of the murine MHC-
class II genes (Sonderstrup G 1999, Vandenbark AA 2003). However, 
appropriate models for hemophilia A were still missing. To overcome this 
limitation, Baxter Innovations GmbH developed a humanized murine 
model for hemophilia A in which the regulation of anti-FVIII immune 
responses is driven by FVIII-derived peptides that are presented by the 
human MHC-class II haplotype HLA-DRB1*1501 (Reipert et al 2007). 
 
Comparative immunogenicity of rVWF and PEG-rVWF in humanized 
E17 mice: study 1 
The aim of the study was to compare the immunogenicity of rVWF and 
PEG-rVWF. Mice were treated with different doses, in the presence or 
absence of the FVIII product ADVATE, which is Baxter’s human 
recombinant FVIII (Table 3: Study design). All samples were tested twice 
for anti-PEG antibodies. Murine anti-PEG antibodies were used as positive 
control. Unstained beads and beads incubated with the secondary 
antibody only were taken as negative control. 
 
Table 3: Study design of study 1: comparative immunogenicity of rVWF and PEG-rVWF in 
mice 
Group animal number Target dose
1 10 FVIII only
male 1 µg in 200µl
2 10 VWF only
male 20 µg in 200 µl
3 10 PEG-VWF only
male 20 µg in 200 µl
4 10 VWF+FVIII
male 20 µg VWF + 1 µg FVIII in 200 µl
5 10 PEG-VWF+FVIII
male 20 µg PEG-VWF + 1 µg FVIII in 200 µl
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The mice were treated after following schedule: 
 
 
Figure 11: Treatment schedule for study 1: comparative immunogenicity of rVWF and 
PEG-rVWF in mice 
 
Comparative immunogenicity of rVWF and PEG-rVWF in humanized 
E17 mice: study 2 
The aim of the study was to compare the immunogenicity of rVWF and 
PEG-rVWF. Mice were treated with different doses, in the presence or 
absence of the FVIII product ADVATE, which is Baxter’s human 
recombinant FVIII (Table 5). All samples were tested twice for anti-PEG 
antibodies. All samples were titrated with PBS starting with a 1:20 dilution 
to define the FACS titer endpoint. FACS titer endpoints were converted to 
FACS log 2 titer values: 
 
Table 4: FACS titer endpoint conversion to FACS titer log 2 values 
 
FACS Titer endpoint FACS titer log 2 
<1:20 0
1:20 1
1:40 2
1:80 3
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Murine anti-PEG antibodies were used as positive control. Unstained 
beads and beads incubated with the secondary antibody only were taken 
as negative control.  
 
 
Figure 12: Treatment schedule for study 2: comparative immunogenicity of rVWF and 
PEG-rVWF in mice 
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Table 5: Study design for study 2: comparative immunogenicity of rVWF and PEG-rVWF 
in mice 
1817 1792
1822 1796
1831 1797
1 1832 7,5 µg rVWF (300 µg/kg)  in 200µl i.v. 6 1798
1833 1799
1839 1803
1840 1804
1841 1655
1842 1660
1848 1669
1849 1672
1850 1673
1852 1678
1859 1679
2 1867 7,5 µg PEG-rVWF (300 µg/kg) in 200µl i.v. 7 1682
1873 1686
1874 1687
1880 1688
1883 1693
1884 1700
1885 1702
1891 1703
1892 1739
1893 1740
3 1894 15 µg rVWF (600 µg/kg)  in 200µl i.v. 8 1741
1895 1742
1898 1749
1903 1753
1904 1755
1909 1757
1912 1763
1918 1766
1919 1770
1921 1591
4 1928 15 µg PEG-rVWF (600 µg/kg)  in 200µl i.v. 9 1601
1785 1612
1935 1613
1779 1616
1783 1617
1784 1619
1467 1638
1471 1639
1472 1640
1473 1641
5 1474 200 µl Formulation Buffer 10 1643 2,5 IU (100 IU/kg) Advate  in 200 µl
1480 1564
1490 1572
1498 1580
1502 1581
1503 1583
1538
1543
1544
1550
11 1551 5,0 IU (100 IU/kg) Advate  in 200 µl
1558
1559
1506
1512
1514
Group number target dose
2,5 IU (100 IU/kg) Advate + 7,5 µg 
PEG-rVWF (300 µg/kg)   in 200 µl
5,0 IU (200 IU/kg) Advate + 15,0 
µg rVWF (600 µg/kg)   in 200 µl
5,0 IU (200 IU/kg) Advate + 15,0 
µg PEG-rVWF (600 µg/kg)   in 200 
µl
Group number target dose
2,5 IU (100 IU/kg) Advate + 7,5 µg 
rVWF (300 µg/kg)   in 200 µl
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3.2.8 Defining the cut off and validation of the anti-PEG detection 
assay in rat 
The aim of these experiments were on the one hand to define the cut off in 
mice, that was needed to distinguish between positive and negative 
plasma samples. On the other hand the anti-PEG antibody detection 
assay in rat had to be validated to comply with quality requirements. 
 
Cut off definition 
To monitor potential antibody development it was necessary to define a 
cut off to be able to distinguish between a positive and a negative sample. 
For this purpose, blood was taken from 20 untreated rats and the plasma 
was screened using the anti-PEG antibody detection assay in different 
dilutions for anti-PEG antibodies. The experiment was repeated 5 times. 
The results of the 1:10 dilution were used to calculate the cut off with the 
software SPSS using the 95% percentile approach. 
 
Validation 
Aim of this study was to describe the assessment of a flow cytometry 
(FACS) based method to detect and to titer antibodies of the IgG subclass 
originating from rat plasma that are directed against polyethylene glycol 
(PEG). For this purpose, inter- and intra-assay variation, specificity and 
linearity was assessed to test the reliability and accuracy of the method. 
For inter-assay variation positive and negative control items were analyzed 
on 10 different days. For intra-assay variation positive and negative control 
items were analyzed in 10 parallels on the same day. Test items were 
serially diluted till the last positively assessed dilution was found (titer 
endpoint). A monoclonal IgG anti-PEG antibody from rabbit was spiked 
with a dilution of 1:1024 into negative rat plasma and used as positive 
control. The antibody was conjugated before with a fluorochrome using the 
APC conjugation KIT from AbD Serotec. Pooled negative rat plasma was 
used as negative control. 
 
 
 
  Material and Methods 
  49/89 
Calculations 
For each dilution, the respective median fluorescence intensity (MFI) 
provided the basis for evaluation. The dilution was assessed as positive if 
the MFI was ≥41,20 due to the definition of the cut off. The dilution was 
assessed as negative if the MFI was <41,20. The last dilution of the serial 
dilution analyzed that was found to be positive was defined as the titer 
endpoint. The titer endpoint that was most common in all analysis was 
defined as the mode titer.  
 
For assessment of specificity of the assay, positive and negative control 
items were analyzed following pre-incubation with soluble PEG or with 
PBS. Samples were measured at an initial 1:20 dilution but not serially 
diluted to identify the corresponding titer endpoint. Samples were 
compared at a 1:20 dilution based on their MFI signal. Since the MFI 
signals were the raw data to calculate the corresponding titer endpoint, this 
procedure reflected also a reliable approach to prove specificity. The 
acceptance criteria was re-defined as follows:  
• Positive control items should be assessed as positive. 
• Negative control items need to be assessed as negative. 
• Pre-incubation of positive control items should result in a negative 
assessment of the sample. 
Pre-incubation of negative control items should have no impact on 
assessment. 
 
3.2.9 Monitoring of potential anti-PEG antibody developing in rats 
treated with PEGylated proteins 
The purpose of this study was to evaluate the potential toxicity of a 
PEGylated recombinant factor VIII (rFVIII) administered intravenously in 
rats every other day for 30 days (15 doses). This study was conducted in 
accordance with FDA Regulations for Good Laboratory Practice (GLP), 21 
CFR Part 58 (Ref 1). 
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Table 6: Study design for 30-day intravenous toxicity study in rats 
        Animal Numbers
Group Article Target Dose  Volume Males Females
(mg/kg/dose) (mL/kg/dose)
1 ADVATE (rFVIII) 0,4 20 129-140 177-188
2 Formulation buffer 0 5 141-152 189-200
3 PEG-rFVIII 0,4 5 153-164 201-212
4 PEG-rFVIII 0,8 5 165-176 213-224
 
 
Dose justification and administration 
Based on a maximum weekly clinical dose of ADVATE of 160 IU/kg 
administered 5 times/week (800 IU/kg/week) and specific activity ranging 
from 4000 – 10000 IU/mg protein, the maximum weekly clinical dose of 
rFVIII an a protein basis is 0,2-0,08 mg/week. The targeted high-dose for 
PEG-rFVIII of 0,8 mg/kg/dose every other day or approximately 3,5 times 
a week represents a weekly rFVIII dose of 2,8 mg/kg/week on a protein 
basis. Therefore, the targeted high dose of PEG-rFVIII is 14-35 times 
higher than the proposed maximum clinical dosage. 
 
The targeted dose for ADVATE, the reference control article, of 0,4 
mg/kg/dose or 7 times/week represents a weekly rFVIII dose of 2,8 
mg/kg/week on a protein basis, which is equivalent to the high dose test 
article. 
 
The calculated volume of test or control article was administered 
intravenously via a tail vein at a rate of approximately 2 mL/min. The 
intravenous route of administration was selected for this study because it 
is the intended route of human exposure in the clinical situation. Doses 
were adjusted weekly based on changes in body weight. 
 
Blood was collected prior to dosing and after the last dose. Blood samples  
were processed for collection of plasma and analyzed for anti-PEG 
antibodies. 
 
Each sample was analyzed two times using the anti-PEG detection assay 
to define the FACS titer endpoint. The titer endpoint is given in log 2 titer 
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values and the average from both runs was calculated. Then the FACS 
titer log 2 values from pre- and post - immunization were compared. A 
sample was evaluated positive when the difference between log 2 titer 
values from pre-immunization and from post-immunization is ≥ 2. 
 
A monoclonal IgG anti-PEG antibody from rabbit was spiked with a dilution 
of 1:1024 into negative rat plasma was used as positive control. The 
antibody was conjugated before with a fluorochrome using the APC 
conjugation KIT from AbD Serotec. Pooled negative rat plasma was used 
as negative control. 
 
3.2.10 Experimental set up for screening human plasma samples for 
natural anti-PEG antibodies 
The aim of this study was to evaluate the incidence of anti-PEG antibodies 
within a healthy human population. This study in healthy blood donors 
provides important information for the screening of patients to be included 
in clinical studies of the new drug candidates. 
 
The human plasma samples from healthy donors are provided by Baxter 
Plasma Sourcing. The samples were 1:10 pre-diluted with PBS to obtain a 
final concentration of 1:20 within the anti-PEG antibody detection assay. It 
is not possible to define a clear cut off due to the fact that there are no 
human individuals that have never been exposed to PEG. Therefore a 
different way of distinction between positive and negative samples had to 
be found. Each plasma sample was analyzed twice: First the samples 
were pre-incubated with 5µl of soluble PEG (wt 200) for 30 minutes at 
room temperature, then the other samples were incubated with 5µl PBS. 
Plasma samples that showed a significant reduction in their MFI value 
when pre-incubated with soluble PEG in comparison to pre-incubation with 
PBS, were counted as positive.  
 
A monoclonal rabbit IgG anti-PEG antibody was used as a positive control. 
Unstained beads and the beads incubated with the secondary antibody 
only and soluble PEG were taken as negative control. 
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4. Results 
4.1 Establishing the anti-PEG antibody detection assay 
4.1.1 First experiments 
A protein A purified IgG antibody from rabbits that were immunized before 
with PEG-FVIII was taken as a positive control while establishing the anti-
PEG antibody detection assay. Figure 13 shows the positive control after a 
serially dilution with PBS was done. Starting with a 1:2 dilution (rabbit 
charge 1 IgG 1), 8 dilutions were done.  
 
 
Figure 13: anti-PEG antibody detection with a protein A purified rabbit IgG antibody 
 
Concentration of the beads 
To see whether the concentration of the beads has an influence on the 
detection of the anti-PEG antibodies or not, a titration of the beads was 
done. 
sample name                 Median 
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Figure 14: Influence of the concentration of TentaGel beads on the detection of anti-PEG 
antibodies 
 
Titration of monoclonal anti-PEG antibodies (IgG, IgM) and of 
secondary antibodies in mouse 
The aim of this experiment was to find out the best dilution for the 
antibodies used for analyses. Lowering the concentration of the antibody 
to a point that would be necessary to see a positive signal, enabled us to 
exclude unspecific binding on the one hand, and on the other hand reduce 
the costs of each experiment. Figure 15 and Figure 16 show examples of 
the titration for the monoclonal IgM anti-PEG antibody. The combination of 
an 1:32 dilution of the primary antibody together with a dilution of 1:32 of 
the secondary antibody showed in all experiments the most stable positive 
signal with the lowest concentration. 
sample name                   Median 
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Figure 15 : Titration of a monoclonal IgM antibody directed against polyethylene glycol 
 
 
 Figure 16: Titration of the secondary antibody with a dilution of the primary antibody of 
1:32 
 
sample name                Median 
sample name                Median 
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4.1.2 Comparison of TentaGel beads and TentaGel beads coupled to 
branched PEG 
TentaGel resins are grafted copolymers consisting of a low cross-linked 
polystyrene matrix on which polyethylene glycol is grafted. The copolymer 
contains about 50 - 70 % PEG (w/w). Therefore, the properties of these 
polymers are highly dominated by the properties of PEG and no longer by 
the polystyrene matrix (Rapp Polymer GmbH). However, the polyethylene 
glycol that was used in this approach was linear, but the polyethylene 
glycol used for PEGylation of recombinant factor FVIII had a branched 
chain. Therefore the TentaGel beads were additionally PEGylated with our 
branched PEG reagent using the same PEGylation reaction as used for 
the PEGylation of recombinant factor VIII. The additional PEGylation 
should cover all possible epitopes, and therefore all possible antibodies 
directed against PEG, within the test. To study if the additional PEGylation 
had an influence on the anti-PEG antibody detection assay, a comparison 
with untreated TentaGel beads using plasma sample of mice that 
contained anti-PEG antibodies was done. 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 17: Comparison of TentaGel beads with and without additional PEGylation, using 
mice plasma samples. The mice have been treated intravenously with PEGylated protein. 
 
Beads without additional 
PEGylation 
     Beads with additional
PEGylation 
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As shown in figure 17 the additional PEGylation had an influence on the 
assay. The samples tested for anti-PEG antibodies using beads coupled to 
branched PEG showed the same or even a higher median fluorescence 
intensity. Moreover beads coupled to branched PEG showed a reduced 
auto fluorescence (figure 18) and were easier to handle because of a 
reduced tendency to aggregate. 
 
 
 
Figure 18: Analyses of auto fluorescence comparing TentaGel beads with and without 
additional PEGylation. 
 
4.1.3 Storage and stability of the beads 
Another important issue was to ensure that the beads used for analyses 
are stable, first of all in terms of PEGylation, and how to store them best 
without destabilizing. To encounter that question, one lot of the beads was 
stored under 4°C and tested several times during a time period of 4 
weeks. In addition three different batches of beads with additional 
PEGylation were produced and lyophilized. Every batch was stored under 
3 different conditions, namely 4°C, room temperatur e and 37°C. Analyses 
were done shortly after production and after 4 weeks of storing (figure 20). 
 
sample name                         Median 
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As you can see in figure 19 the beads showed no significant change in 
their median fluorescence intensity. However, to ensure that the beads of 
the same lot would be stable during a whole preclinical or clinical study, 
they got lyophilized after PEGylation reaction with the branched reagent. 
 
Figure 19: Storage of TentaGel beads under 4°C and analyzed s everal times within one 
month with a protein A purified anti-PEG antibody from rabbit. 
 
 
Figure 20: Comparison of different batches of TentaGel beads with additional PEGylation; 
all batches were stored for 4 weeks under 3 different conditions, 4°C, room temperature 
and 37°C. The beads were tested with a protein A pu rified anti-PEG antibody from rabbit, 
before and after storage. 
sample name   Median 
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4.1.4 Competition Assay 
To study whether the antibodies contained in our plasma samples are 
specific for PEG, a competition assay was done. As you can clearly see in 
figure 21, the positive control alone had a very high median fluorescence 
intensity (MFI) of 2938. When you pre-incubate with the soluble PEG the 
MFI goes down to 113, and up again if you dilute the soluble PEG before 
pre-incubation. 
 
 
 
Figure 21: Competition Assay: A monoclonal anti-PEG antibody was pre-incubated with a 
soluble PEG (wt=200) in different dilutions, before they were mixed together with the 
TentaGel beads. 
sample name                         Median 
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4.2 Anti-PEG antibodies in mouse 
4.2.1 Defining the cut off 
To monitor potential antibody development it was necessary to define a 
cut off to be able to distinguish between a positive and a negative sample. 
For this purpose, blood was taken from 53 untreated mice and the plasma 
was screened in different dilutions for anti-PEG antibodies.  
 
Figure 22: Titration analyses of plasma from a naïve mouse. The positive control was a 
monoclonal anti-mouse anti-PEG antibody. 
 
For the cut off analyses only the values from the plasma with a 1:20 
dilution were taken. 
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Table 7: Analyses of plasma from untreated mice in a 1:20 dilution. 
Cut off definition for anti-PEG antibody in mouse
plasmadilution: 1/20
MFI  PE (IgM) MFI APC (IgG) MFI  PE (IgM) MFI APC (IgG)
animal 1 8,33 1,37 animal 31 9,25 2,19
animal 2 8,2 1,37 animal 32 9,82 1,76
animal 3 8,17 1,4 animal 33 10,1 2,05
animal 4 8,08 1,36 animal 34 9,29 2,59
animal 5 7,87 1,4 animal 35 9,95 1,93
animal 6 10,3 2,09 animal 36 6,07 1,83
animal 7 10,8 1,73 animal 37 7,7 2,08
animal 8 10,9 1,69 animal 38 6,7 1,29
animal 9 9,85 1,64 animal 39 7,36 1,14
animal 10 9,88 1,62 animal 40 6,72 1,08
animal 11 11,7 1,68 animal 41 6,88 1,04
animal 12 10,5 1,73 animal 42 6,92 1,04
animal 13 8,26 1,78 animal 43 6,87 1,03
animal 14 8,33 1,69 animal 44 6,99 1,01
animal 15 7,98 1,66 animal 45 7,57 1,04
animal 16 8,37 1,75 animal 46 8,98 1,14
animal 17 7,74 1,83 animal 47 9,13 1,05
animal 18 7,87 1,88 animal 48 8,9 2,12
animal 19 8,85 1,72 animal 49 9,04 2,7
animal 20 9,15 2,83 animal 50 8,62 2
animal 21 8,78 3,28 animal 51 8,66 2,34
animal 22 8,88 2,72 animal 52 9,01 2,39
animal 23 9,63 2,49 animal 53 8,77 2,37
animal 24 9,35 2,55
animal 25 9,85 2,78
animal 26 9,35 2,67
animal 27 9,83 2,59
animal 28 9,1 1,93
animal 29 9,4 1,85
animal 30 10,2 1,89
MFI = Median Fluorescence Intensity
 
 
From the results presented in table 7 the 95% percentile was calculated 
and defined as cut off. 
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Figure 23: Calculation of the 95% percentile by SPSS (Figure 23A) for mouse IgM anti-
PEG antibody MFI values and a histogram showing the absolute frequency of all values in 
the data set(Figure 23B). 
 
 
 
 
 
 
Cut off= 10,83 
Figure 23 B 
Figure 23A 
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Figure 24: Calculation of the 95% percentile by SPSS (Figure 24A) for mouse IgG anti-
PEG antibody MFI values and a histogram showing the absolute frequency of all values in 
the data set (Figure 24B) 
 
4.2.2 Monitoring of potential anti-PEG antibody developing in mice 
treated with PEGylated proteins 
The anti-PEG antibody detection assay was used to monitor the 
development of anti-PEG antibodies in several preclinical studies of 
PEGylated protein product candidates. In the course of the factor VIII Half-
life (FVIII-HL) project (extension of the factor VIII half-life), von Willebrand 
Cut off= 2,79 
Figure 24 B 
Figure 24A 
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factor (VWF) was PEGylated. VWF is the carrier molecule of FVIII. The 
aim of series 1 and series 2 in mice was to compare the immunogenicity of 
recombinant von Willebrand factor (rVWF) and PEGylated rVWF in 
humanized E17 mice. 
 
Comparative immunogenicity of rVWF and PEG-rVWF in humanized 
E17 mice: study 1 
 
 
Figure 25: Development of IgM anti-PEG antibodies during the comparative 
immunogenicity study of rVWF and PEG-rVWF: study 1  
negative samples 
weak positive samples 
strong positive samples 
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Figure 26: Development of IgG anti-PEG antibodies during the comparative 
immunogenicity study of rVWF and PEG-rVWF: study 1 
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Comparative immunogenicity of rVWF and PEG-rVWF in humanized 
E17 mice: study 2 
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Figure 27: Development of anti-PEG IgM antibodies during the comparative 
immunogenicity study of rVWF an PEG-rVWF in humanized E17 mice: study 2. The 
diagram shows the anti-PEG IgM antibodies as log 2 FACS Titer values. 
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Comparative Immunogenicity of rVWF and PEG-rVWF
0
1
2
3
4
Ti
te
r 
o
f a
n
ti-
PE
G
 
Ig
G
 
an
tib
o
di
es
 
(lo
g2
)
group 1 - 7,5µg rVWF in
200µl i.v.
group 2 - 7,5µg PEG-
rVWF in 200µl i.v.
group 3 - 15µg rVWF
in200µl i.v.
group 4 - 15µg PEG-
rVWF in 200µl i.v.
group 5 - 200µl
formulation buffer
group 6 - 2,5 IU Advate +
7,5µg rVWF in 200µl
group 7 - 2,5 IU Advate +
7,5µg PEG-rVWF in
200µl
group 8 - 5,0 IU Advate +
15µg rVWF in 200µl
group 9 - 5,0 IU Advate +
15µg PEG-rVWF in 200µl
Figure 28: Development of anti-PEG IgG antibodies during the comparative 
immunogenicity study of rVWF an PEG-rVWF in humanized E17 mice: study 2. The 
diagram shows the anti-PEG IgM antibodies as log 2 FACS Titer values.  
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4.3 Anti-PEG antibodies in rat 
4.3.1 Defining the cut-off 
To monitor potential anti-PEG antibody development in rats, it was 
necessary to define a cut off to be able to distinguish between a positive 
and a negative sample. For this purpose, blood was taken from 20 
untreated rats and the plasma was screened in different dilutions for anti-
PEG antibodies. The same samples were analyzed on 5 different days. 
 
Table 8: Analyses of plasma from untreated rats in a 1:10 dilution with 5 repeats. 
Cut-Off definition for anti-PEG antibody detection assay in rat
citrated rat plasma obtained from untreated rats
Dilution 1/10
Replica 1 Replica 2 Replica 3 Replica 4 Replica 5
Male MFI APC (IgG) MFI APC (IgG) MFI APC (IgG) MFI APC (IgG) MFI APC (IgG)
1 42,8 28,8 40 35,4 34,6
2 39,5 27,7 42,6 32,7 35,6
3 34,1 27 39,7 32,9 39,2
4 41,2 27,4 40,8 32,6 34,6
8 37,1 26,2 40,6 33,4 40,4
9 39,4 25,8 36,4 32,5 35,5
10 41,1 28,1 37,8 32,5 35,2
18 37,7 23,3 38,4 31,2 36,9
19 35,5 21,2 37,9 32,8 35,4
20 39,8 27,5 42 32,9 34,7
Female
5 35,8 25,1 38,1 31,0 34,3
6 34,1 24,3 37,9 30,5 34,0
7 40 25,3 43,3 32,6 33,8
11 37,3 25,9 36,4 31,0 34,2
12 37,8 27,3 35,1 31,3 33,9
13 34 25,8 37,2 30,7 34,6
14 34,5 25,7 36,8 31,1 35,0
15 34,2 33,7 38 32,7 36,5
16 38,3 33,4 34,1 32,5 34,3
17 36,1 25,9 33,4 32,4 34,6
unstained 33,4 25,4 39,6 33,8 34,1
 
The results of this assay were used to calculate the cut off with the 
software SPSS using the 95% percentile approach.  
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Figure 29: Calculation of the 95% percentile by SPSS (Figure 29A) for rat IgG anti-PEG 
antibody MFI values and a histogram showing the absolute frequency of all values in the 
data set (Figure 29B). 
 
4.3.2 Validation of the anti-PEG antibody detection in rat for further 
studies under GLP-conditions 
The aim of this study was to describe the assessment of a flow cytometry 
(FACS) based method to detect and to titer anti-PEG antibodies of the IgG 
subclass originating from rat plasma. For this purpose inter-assay variation 
(table 9), intra-assay variation (table 10), specificity (table 11) and linearity 
(figure 29) for this method were obtained. 
 
Cut off=41,20 
Figure 29B 
Figure 29A 
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Inter-assay variation 
 
Table 9 : Inter-assay variability (titer endpoints given as log 2 titer values) 
 
 
Intra-assay variation 
 
Table 10: Intra-assay variability (titer endpoint given as log 2 titer values) 
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Specificity 
 
Table 11: Specificity (MFI values given) 
Specificity
with with
 antigen  antigen
nd nd 151 nd
not detectable: MFI< 41,20 at 1:20 dilution
negative control item positive control item
without 
antigen
without 
antigen
 
 
Linearity 
The relationship between antibody titer and MFI values was characterized 
graphically. 
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Figure 30: Linearity between antibody titers and MFI values. 
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4.3.3 Monitoring of potential anti-PEG antibody developing in rat 
The purpose of this study (table 12: study design) was to evaluate the 
potential toxicity of a PEGylated recombinant factor VIII (rFVIII) 
administered intravenously in rats every other day for 30 days (15 doses). 
This study was conducted in accordance with FDA Regulations for Good 
Laboratory Practice (GLP), 21 CFR Part 58 (Ref 1). 
 
Table 12: Study design 
  Animal Numbers
Group Article Target Dose  Volume Males Females
(mg/kg/dose) (mL/kg/dose)
1 ADVATE (rFVIII) 0,4 20 129-140 177-188
2 Formulation buffer 0 5 141-152 189-200
3 PEG-rFVIII 0,4 5 153-164 201-212
4 PEG-rFVIII 0,8 5 165-176 213-224
 
 
Blood was collected prior to dosing and after the last dose. Blood samples 
were processed for collection of plasma and analyzed for anti-PEG 
antibodies. 
 
Each sample was analyzed two times using the anti-PEG detection assay 
to define the FACS titer endpoint. The titer endpoint is given in log 2 titer 
values and the average from both runs was calculated. Then the FACS 
titer log 2 values from pre- and post - immunization were compared. A 
sample was evaluated positive when the difference between log 2 titer 
values from pre-immunization and from post-immunization is ≥ 2. 
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The results presented in table 13 were summarized in figure 30 and figure 
31 
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Figure 31: Diagram of anti-PEG FACS titers from rat plasma samples taken before 
immunization 
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Figure 32: Diagram of anti-PEG FACS titers from rat plasma samples taken after 
immunization 
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4.4 Anti-PEG antibodies in healthy human donors 
The aim of this study was to evaluate the incidence of anti-PEG antibodies 
within a healthy human population. This study in healthy blood donors 
provides important information for the screening of patients to be included 
in clinical studies of the new drug candidates. In figure 33 you can see an 
example of a anti-PEG IgG positive plasma sample with a MFI of 46.6. 
After pre-incubation with soluble PEG, the MFI goes down to 10.7. 
 
 
Figure 33: Example of a IgG anti-PEG positive human plasma sample The soluble PEG 
was given in a 5% concentration of total volume.  
 
Table 14: Screening of human plasma samples from healthy donors. Samples were 
analyzed for IgG and IgM anti-PEG antibodies 
Human Plasma Sample - Analyses
492 samples of healthy human plasma donors
positive samples 94 19,10%
IgG positive only 30 6,10%
IgM positive only 55 11,18%
IgG/IgM positive 9 1,83%
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5. Discussion 
A number of protein therapeutics have been successfully conjugated with 
polyethylene glycol (PEG) in order to increase the serum half-life and to 
reduce immunogenicity of these proteins. It was shown in recent reports 
that treatment with PEGylated protein therapeutics leads to the 
development of anti-PEG antibodies in animal disease models and 
patients. These antibodies caused a rapid clearance of the PEGylated 
proteins from the circulation (Armstrong et al 2006). Moreover, a 
considerable amount of anti-PEG antibodies in healthy donors was 
reported in contrast to previous studies (Armstrong et al 2003). 
 
The findings of anti-PEG antibodies raise the question whether 
1. the presence of anti-PEG antibodies may alter the pharmacokinetic 
profile of the PEGylated conjugate and eventually render treatment 
less effective or ineffective, necessitating a modification of dosing 
recommendations; 
2. PEGylated coagulation factors induce anti-PEG antibodies leading 
to a less effective treatment as mentioned in patients with 
hemophilia. 
 
The objective of my project was to establish an assay for the detection of 
anti-PEG antibodies. This assay should be suitable for monitoring the 
development of anti-PEG antibodies in animal disease models, in healthy 
human plasma donors and finally in patients treated with PEGylated 
proteins. The study in healthy blood donors should provide important 
information for the screening of patients to be included in clinical studies of 
the new PEGylated drug candidates. 
 
Based on the results obtained in my project we can conclude that the flow 
cytometric approach to detect anti-PEG antibodies in plasma is a suitable 
approach that meets the requirements of accuracy, reproducibility and 
specificity. Moreover the new assay represents a significant improvement 
in comparison to earlier detection methods (Fisher et al).  
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5.1 Anti-PEG antibody detection assay 
After the initial experimental set up was established, several studies had to 
be done in order to meet the requirements for the test: 
 
 All antibodies to be used had to be titrated to find out the best 
concentration that would give an optimal signal to noise ratio. A 
combination of an 1:32 dilution of the primary antibody together with a 
dilution of 1:32 of the secondary antibody provided the optimal signal to 
noise ratio. 
 
 The optimal concentration of the TentaGel beads had to be found. Our 
results after changing the concentration of the beads showed no difference 
in median fluorescence intensity (MFI) at all. 
 
 In the early phase of developing the assay we decided to modify the 
TentaGel beads by adding a branched PEG reagent to the functional group 
of the linear PEGs that are grafted on the surface of the beads. This 
branched PEG is the same that Baxter Innovations GmbH is currently 
using to modify FVIII or VWF in order to increase the half life of Factor VIII. 
The additional PEGylated beads have the advantage of covering all 
potential epitopes that maybe present within the PEGylated protein 
therapeutics. After comparing both type of beads, the results show the 
median fluorescence intensities of the assay run with additional PEGylation 
of the beads, were the same or even higher than the run without additional 
PEGylation. The anti-PEG antibody detection assay with the additional 
PEGylated beads has an increased sensitivity, which could be to the 
enlargement of the PEG-surface on the beads through the branched PEG. 
Moreover, the additional PEGylation of the beads has some more 
advantages. First of all the beads seem to be less auto fluorescence. This 
result was seen in almost every experiment where we compared both type 
of beads with each other. Another improvement we noticed is an easier 
handling of our modified TentaGel beads due to almost no aggregation. 
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 We could show that after coupling the TentaGel beads with a branched 
PEG reagent, the stability of the beads was maintained. However, to 
ensure that the beads of the same lot would be stable during a whole 
preclinical or clinical study, we decided to lyophilize the TentaGel beads 
after the PEGylation reaction and test the lyophilized beads for stability 
under different conditions. Our results demonstrate, that the PEGylated 
beads are stable for at least 4 weeks. 
 
 An important issue was to proof the specificity of the test. For this 
purpose we did a competition assay. We observed a reduction of the MFI 
after pre-incubation with the competitor and an increase again after diluting 
the competitor. Based on these results, we conclude that the detected 
antibodies in our assay were specifically directed against PEG. 
 
 To monitor the potential development of anti-PEG antibodies in disease 
models it was necessary to define a cut off to be able to distinguish 
between a positive and a negative sample. For this purpose, blood was 
taken from untreated mice or rats and the plasma was screened using the 
anti-PEG antibody detection assay. Non of the animals tested showed a 
MFI value above background., It seems that there are no natural anti-PEG 
antibodies in mice or rats, which is exactly the result we would expect, due 
to the fact that they have never been confronted with PEG in their life. The 
results were taken to define the cut off using the 95% percentile, which 
means that we include in our assay 5% of false positive. 
 
 A validation study had to be done to comply with quality requirements 
that were necessary to monitor potential development of anti-PEG 
antibodies in rat plasma within a study under Good Laboratory Practice 
(GLP) conditions. For this purpose, inter- and intra-assay variation, 
specificity and linearity were assessed to proof the reliability and accuracy 
of the method. We could proof the accuracy, reproducibility and specificity 
of the anti-PEG detection assay. Therefore the test fulfilled all requirements 
to work under GLP conditions. 
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5.2 Anti-PEG antibodies in mouse 
In the course of the factor VIII Half Life project two proteins were 
PEGylated to elongate the half life of FVIII: rFVIII and rVWF, the carrier 
molecule of FVIII. Two studies were done in mice to compare the 
immunogenicity of rVWF and PEGylated rVWF. The potential development 
of anti-PEG antibodies was monitored.  
 
As our results from study 1 show, no animal from a group that was treated 
with proteins without PEGylation showed an immune reaction. On the 
other hand we could detect anti-PEG antibodies in some animals in both 
groups that were treated with PEGylated proteins. From these results we 
conclude, that IgM and IgG anti-PEG antibodies develop after treatment 
with PEGylated proteins. 
 
Study 2 had a similar study design as study 1, but there were major 
differences in the results: not only groups that were treated with 
PEGylated proteins showed anti-PEG antibodies. Even animals that just 
received formulation buffer showed a log 2 titer of 3. On the other hand 
only animals that were treated with PEGylated proteins developed IgG 
anti-PEG antibodies. One possible explanation for the results we obtained 
in study 2 may be a general, unspecific immune reaction of the animals 
due to an viral or bacterial infection. 
 
5.3 Anti-PEG antibodies in rat  
The aim of the 30-days intravenous toxicity study in rats was to evaluate 
the potential toxicity of a PEGylated recombinant FVIII administered 
intravenously in rats every other day for 30 days (15 doses). This study 
was conducted in accordance with FDA Regulations for Good Laboratory 
Practice (GLP). We had 4 different groups with different target doses. 
Blood was taken before and after treatment and the plasma was analyzed 
for anti-PEG antibodies. It can be seen that only 2 animal showed a titer of 
anti-PEG antibodies after treatment with PEGylated protein, and only one 
from these animals was counted as positive, because the difference 
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between log 2 titer values from pre-immunization and from post-
immunization was ≥ 2. We could not see any development of anti-PEG 
antibodies within this study in rats. We conclude from our results that most 
of the animals were becoming tolerant for PEG after receiving repeated 
high doses of PEG within one month. 
 
5.4 Anti-PEG antibodies in humans 
The aim of this study was to evaluate the incidence of anti-PEG antibodies 
within a healthy human population. This study in healthy blood donors 
provide important information for the screening of patients to be included 
in clinical studies of the new drug candidates. Our study confirmed former 
results that pre-formed anti-PEG antibodies are occurring more often then 
expected, related to studies in the 1980s (Armstrong et al, ASH 2003) and 
present a major concern for the development of any PEGylated protein 
therapeutic, that should be considered. Nowadays PEG is widespread in a 
lot of different products, starting from make-up and food to therapeutics. 
Whether those antibodies that we detected in healthy human plasma 
donors are natural occurring antibodies or are pre-formed because the 
human individuals were confronted with PEG all their live, is yet unclear. 
To answer this question I suggest To analyze the B-cell receptor for 
somatic mutations. This would be a proof for affinity maturation by somatic 
hypermutations. 
. 
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5.5 Overall conclusion 
We established a flow cytometric anti-PEG antibody detection assay that 
is accurate, reliable, reproducible and specific. Therefore, the assay fully 
complies with quality requirements that are necessary to run the test under 
FDA Regulations for Good Laboratory Practice (GLP). In addition we could 
show that the modification of the TentaGel beads provided a major 
improvement of the anti-PEG antibody detection assay. 
 
Our results within the animal disease models indicate, that there is a 
potential to develop anti-PEG antibodies after treatment with PEGylated 
protein therapeutics. We did not see an immune reaction to PEGylated 
rFVIII. However, we could see antibody developing in animal disease 
models when treated with PEGylated rVWF. Maybe some epitopes get 
covered when PEG is attached to FVIII and therefore no immune reaction 
could be seen. Or the PEGylation of rVWF forms new epitopes and cause 
antibody developing. Those antibodies may recognize epitopes as well 
that we are presenting within our assay. Another possible explanation 
could be the different treatment schedules used in the studies. The study 
in rats with the PEGylated rFVIII used very high and repeated doses within 
one month. Therefore it is likely that the animals were becoming tolerant 
for PEG. 
 
Our study with healthy human plasma donors confirm prior results that 
natural anti-PEG antibodies are occurring more often then expected, 
relating to studies in the 1980s (Armstrong et al, ASH 2003) and present a 
major concern for any PEGylated protein therapeutic development, that 
should be considered. We do not know whether the antibodies that we 
detected in healthy human plasma donors were natural occurring 
antibodies or pre-formed antibodies due to the fact that human individuals 
were confronted all their live with PEG. 
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8. Abbreviations 
 
PEG     Polyethylen Glycol 
FACS     Fluorescence Activated Cell Sorting 
FVIII     blood coagulation factor VIII 
VWF     von Willebrand Factor 
IgG     Immunglobulin G 
IgM     Immunglobulin M 
PE     Phycoerythrin 
APC     Allophycocyanin 
DPBS     Dulbeccos phosphate buffered saline 
NaCl     Sodium Chloride 
HCl     Hydrochloric acid 
WFI     Water For Injection 
MHC     Major Histocompatibility Complex 
HLA     Human leukocyte antigen 
MFI     Median Fluorescence Intensity 
FDA     Food and Drug Administration 
GLP     Good Laboratory Practice 
